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SUMMARY
Fibrillin-1, the main component of 10-12 nm microfibrils of
the extracellular matrix, is synthesized as profibrillin and
proteolytically processed to fibrillin. The putative cleavage
site has been mapped to the carboxy-terminal domain of
profibrillin-1, between amino acids arginine 2731 and
serine 2732, by a spontaneous mutation in this recognition
site that prevents profibrillin conversion. This site contains
a basic amino acid recognition sequence (R-G-R-K-R-R)
for proprotein convertases of the furin/PACE family. In this
study, we use a mini-profibrillin protein to confirm the
cleavage in the carboxy-terminal domain by both
fibroblasts and recombinantly expressed furin/PACE,
PACE4, PC1/3 and PC2. Site-directed mutagenesis of

amino acids in the consensus recognition motif prevented
conversion, thereby identifying the scissile bond and
characterizing the basic amino acids required for cleavage.
Using a PACE/furin inhibitor, we show that wild-type
profibrillin is not incorporated into the extracellular matrix
until it is converted to fibrillin. Therefore, profibrillin-1 is
the first extracellular matrix protein to be shown to be a
substrate for subtilisin-like proteases, and the conversion of
profibrillin to fibrillin controls microfibrillogenesis through
exclusion of uncleaved profibrillin.

INTRODUCTION

systems, either alone or in association with elastin. Little is
known about how fibrillin-1 aggregates into microfibrils, the
control of this process, or the organization (Ramirez, 1996).
Mutations in fibrillin-1 cause Marfan syndrome, a connective
tissue disorder with skeletal, ocular and cardiovascular
complications.
Fibrillin-1 is synthesized as a precursor, profibrillin-1 (350
kDa), which is converted to fibrillin (330 kDa) in a calciumdependent process (Milewicz et al., 1992; Raghunath et al.,
1995). The putative cleavage site was assigned to an R-G-RK-R-R motif in the unique carboxy-terminal domain by the
identification of a point mutation in one fibrillin allele of an
individual with isolated skeletal features of Marfan syndrome
(Milewicz et al., 1995). This mutation alters the arginine in the
P6 position of this motif to a tryptophan (R2726W).
Fibroblasts heterozygous for this mutation converted only onehalf of secreted profibrillin to fibrillin. In order to further
characterize the cleavage site and to confirm that the
furin/PACE family is responsible for processing profibrillin,
we designed a construct encoding a mini-profibrillin protein,
either with (mini-profibrillin) or without (short fibrillin) the
unique carboxy-terminal domain. Inhibitors of profibrillin-1
proteolytic processing were also identified to determine the

Many growth factors, hormones, neuropeptides and plasma
proteins are synthesized as pro-proteins and require proteolytic
processing during secretion to yield a biologically active
protein. Cleavage often occurs after the paired basic amino acid
residues R-R or K-R. The endoproteases responsible for this
process are the family of calcium-dependent serine proteases,
homologous to the yeast propeptidase Kex2 and bacterial
subtilisins (Seidah et al., 1994, 1997). There are currently
seven members of this family: furin/PACE (Paired basic Amino
acid Cleaving Enzyme), PACE4, and the proprotein or
precursor convertases (PCs), PC1/3, PC2, PC4, PC5 and PC7
(Seidah et al., 1994, 1997; Tsuji et al., 1994). The majority of
these enzymes use R-X-K/R-R↓ as the cleavage motif, with the
arginines in the P1 and P4 position being crucial for efficient
processing.
Fibrillin-1 is the major component of 10-12 nm microfibrils
of the extracellular matrix, which are widely distributed not
only in mammals but also in invertebrates (Sakai et al., 1986;
Reber-Muller et al., 1992; Thurmond and Trotter, 1996).
Microfibrils are extracellular aggregates that confer critical
biomechanical properties on a wide variety of tissues and organ
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effect of preventing processing on incorporation of fibrillin-1
into the extracellular matrix. We report that profibrillin is the
first extracellular matrix protein identified that is a substrate for
proprotein convertases of the subtilisin-like type. Furthermore,
our studies indicate that this proteolytic processing is necessary
for the incorporation of fibrillin into microfibrils.
MATERIALS AND METHODS
Mini-profibrillin and short-fibrillin constructs and sitedirected mutagenesis
Four DNA segments representing the N terminus (exon 1), exons 2333, exons 30-44 and the C terminus (exons 64-65) of profibrillin-1
were amplified by RT-PCR using control fibroblast RNA and primers
tailed with unique restriction sites (Table 1). The DNA fragments were
cloned into the pGEM-T vector (Promega, Madison, WI) and
sequenced. The pGEM-T vector containing the N terminus was
digested with XbaI and BsiWI and the purified fragment ligated to the
pGEM-T vector containing exons 23-33. After identification of
correctly ligated clones, the leader sequence and exons 23-33 were
removed from pGEM-T using ApaI and SmaI and inserted into the
clone containing exons 30-44. The overlapping region of the two exon
constructs contained a common SmaI site used to join the fragments
in the proper sequence. The carboxyl terminus was inserted using
unique BspEI and XbaI sites. The constructs were subcloned with or
without the carboxy-terminal sequences into the mammalian
expression vector pcDNA3 (Invitrogen, San Diego) and named
p(LEEC)DNA3 and p(LEE)DNA3, respectively. The derived proteins
were termed mini-profibrillin (with carboxyl terminus) and shortfibrillin (without the carboxyl terminus) (Fig. 1). Short-fibrillin has
five additional amino acids (S-G-L-N-H-Stop) added to the carboxyl
terminus of the EGF domain encoded by exon 44. Site-directed
mutagenesis was done on the wild-type carboxy-terminal sequence in
the pGEM-T vector using primers P1-S and P1-AS (Table 1). Primer
pairs CTERM-S and P1-AS amplified a 200-bp 5′ carboxy-terminal
fragment using the wild-type carboxy-terminal clone/pGEM-T as

template. A 400-bp 3′ fragment was amplified likewise using primer
pair P1-S and CTERM-AS. Equimolar amounts of the amplified
fragments were then used as templates to amplify the full-length
carboxy-terminal fragment (584 bp) using the following conditions:
denaturation at 94°C for 2 minutes, annealing at 55°C for 3 minutes
and extension at 72°C for 1 minute, for 6 cycles. Primers CTERM-S
and CTERM-AS were then added to the reaction and 30 cycles were
done under standard conditions. Amplified fragments were cloned
into pGEM-T and sequenced. The mutant carboxy-terminal fragment
was then substituted for the wild-type sequence in the p(LEEC)DNA3
construct using flanking, unique restriction sites (BspEI and XbaI)
(Figs 1, 2). The same scheme was used for site-directed mutagenesis
to create the mutant P2, P4, P6W and P6A carboxyl terminus clones,
using the appropriate primers (Table 1).
Generation of recombinant proteins
To obtain radiolabelled mini-profibrillin and short-fibrillin, a rabbit
reticulocyte lysate system (TNT kit; Promega) was employed using 1
µg of plasmid DNA. In vitro transcription/translation was carried out
in the presence of [35S]cysteine (Amersham, Arlington Heights, IL).
2 µl of the respective TNT reactions were added to 50 µl of sample
buffer containing 10% mercaptoethanol, and proteins were analyzed
by SDS-PAGE using a 7% polyacrylamide gel and a buffer system
according to Fling and Gregerson (1986). Following synthesis, the
TNT reactions were pre-cleared with normal rabbit serum and
Protein-G Sepharose (Pharmacia, Piscataway, NJ). The identity of the
recombinant proteins was confirmed by immunoprecipitation using a
rabbit polyclonal antibody directed against a bacterially expressed
fusion protein that contained FBN1 amino acids encoded by
nucleotides 4582-4941 (generously provided by Dr Maureen Boxer)
(D’Arrigo et al., 1998).
Conversion analyses of recombinant protein
COS-1 cells were transfected with cDNAs for PACE in the
expression plasmid pMT3, PACE4 in the expression plasmid pNOT,
and PC2 and PC3 both in the expression plasmid pMT3SV2, as
previously described (Rehemtulla et al., 1992, 1993; Wise et al.,
1990). All constructs for the respective proprotein convertases

Table 1. Primers used
(A) Primers used for the generation of mini-profibrillin and short-fibrillin constructs
Name
Size (bp)
Sequence
Leader-S (L)
Leader-AS
Ex 23-33-S (E)
Ex 23-33-AS
Ex 30-44-S (E)
Ex 30-44-AS
CTERM-S (C)
CTERM-AS

199
1466
1764
584

5′-GAATTCGCCACCATGCGTCGAGGGCGTCTG-3′
5′-CCCCTCCGGATCCCGTACGGACATTGGGTCCTTTAAGC-3′
5′-GACTCGTACGGATATAGATGAATGTGAAGTGTTCC-3′
5′-TCCTTCCTTGCACAGACAGCGG-3′
5′-TTGTGTTATGATGGATTCATGG-3′
5′-TCAGTCCGGAATTGCACTGTCCTGTGGA-3′
5′-GTCATCCGGAGCTAGCTCTGGAATGGGCATGGG-3′
5′-GCTCTAGAGCTAGCTTAATGAAGCAAAACCTGGAT-3′

RE sites
EcoRI
BsiWI and BspEI
BsiWI
None*
None*
BspEI
NheI, XbaI
BspEI, NheI, BsiWI

*SmaI site in FBN1 exon 32 cDNA sequence was used.
(B) Primers used for site-directed mutagenesis
Name
P1-S
P1-AS
P2-S
P2-AS
P4-S
P4-AS
P6W-S
P6W-AS
P6A-S
P6A-AS

Sequence

Amino acid change‡

5′-GAAACGGAGcAGCACAAACG-3′
5′-CGTTTGTGCTgCTCCGTTTC-3′
5′-GGCAGGAAAgctAGAAGCACAAACG-3′
5′-CGTTTGTGCTTCTagcTTTCCTGCC-3′
5′-TACCCCAAACGGGGCgcGAAACGGAGAAGC-3′
5′-GCTTCTCCGTTTCgcGCCCCGTTTGGGGTA-3′
5′-GGCTACCCCAAAtGGGGCAG-3′
5′-CTGCCCCaTTTGGGGTAGCC-3′
5′-ATGGCTACCCCAAAgcGGGCAGGAAACGG-3′
5′-CCGTTTCCTGCCCgcTTTGGGGTAGCCAT-3′

R2731S

‡Incorporation of the nucleotides in small letters results in the amino acid substitution indicated.

R2730A
R2728A
R2726W
R2726A
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lacked transmembrane domains so that they were secreted in soluble
form into the culture medium. Accordingly, conditioned culture
media of transfected cells were concentrated up to 36-fold using
Microcon-10 spin columns (Amicon, Beverly, MA). Concentrates
(10 µl) were added to 40 µl of 50 mM sodium acetate buffer, pH
6.0. 2 µl of TNT products and 3 µl of 100 mM CaCl2 (final
concentration 6 mM) were added, followed by incubation at 37°C
for 16-20 hours. Since both mini-profibrillin and short-fibrillin have
three additional dibasic R-R sites in common, 2 µl of either TNT
reaction product were digested in 25 µl of 0.1 M Tris/HCl/6 mM
CaCl2, pH 7.0, with 0.1 units of a specific R-R/K-R endoprotease
(MobiTec, Göttingen, FRG). To monitor conversion by cell cultures,
hyperconfluent fibroblasts, LoVo cells or COS-1 cells (106 cells/35
mm dish) were incubated for 16-24 hours with 700 µl of culture
medium (with or without 2% FCS) containing 10 µl of the respective
TNT reactions.
Metabolic studies
Hyperconfluent fibroblasts heterozygous for the FBN1 mutation
R2726W and control cultures were depleted for 1 hour in 700 µl of
serum-free MEM lacking cysteine (Milewicz et al., 1995). Then 100
µCi of [35S]cysteine were added per culture to pulse the cells for 1
hour. The label was removed and the cells were incubated for 24 hours
in complete MEM containing 5% FCS and antibiotics. Parallel
cultures were preincubated with the furin inhibitor decanoyl-Arg-ValLys-Arg-chloromethylketone (DecRVKR-CMK) during the depletion
step at varying concentrations (Garten et al., 1994). Fresh inhibitor
was then added to the chase medium and every 8 hours thereafter.
Media were collected and extracellular matrices were harvested as
described (Hedman et al., 1979). Briefly, cells were solubilized 3
times with 0.5% desoxycholate, washed once with distilled water and
air dried. The extracellular matrix was scraped from the dish into 250
µl of reducing sample buffer. Media and the first desoxycholate lysate
were precipitated with methanol/chloroform and pellets were
redissolved in 250 µl of sample buffer (Wessel and Flugge, 1984). 70
µl per sample were analyzed by SDS-PAGE and autoradiography
performed.
Confocal laser scanning studies of microfibrils deposited
in cell culture
Fibroblasts from a normal control were seeded at a density of 106
fibroblasts per 35 mm dish on glass coverslips and allowed to attach
for 24 hours. The cells were incubated either in the presence or
absence of 100 µM of the furin inhibitor DecRVKR-CMK, which
was replaced every 12 hours for a further 48 hours. The
hyperconfluent cultures were fixed for 10 minutes in absolute
methanol at −20°C and air dried. After blocking of nonspecific
binding sites with 1% bovine serum albumin/10% normal goat serum
in PBS, cells were incubated overnight at 23°C with monoclonal
antibody mAb69 directed against fibrillin-1 (Maddox et al., 1989).
After several washes in PBS, coverslips were incubated for 1 hour at
room temperature with FITC-coupled goat anti-mouse IgG (Jackson
Immunoresearch). Syto 17 was used as a nuclear counterstain; it has
an excitation spectrum comparable to Texas Red (Molecular Probes,
Leiden, The Netherlands). Preparations were mounted in Mowiol
(Hoechst) in Tris/HCl, pH 8.6. Preparations were examined using a
LSM 410 invert device (Carl Zeiss, Oberkochen, Germany)
combined with 2 HeNe lasers (543/633 nm) and an argon laser (488
nm) for multicolor fluorescence. A 40-fold oil immersion objective
(numerical aperture 1.3) was employed. Extended focus view (10×
0.6 µm) section planes were obtained with identical scanning settings
in order to discriminate differences in fluorescence intensities. In
addition, single sections (0.6-0.7 µm) with optimized scanning
conditions per field were obtained in order to assess microfibril
thickness and density. Photographs were taken on Tmax 3200 ASA
(Kodak) using conventional Axiophot (Zeiss, Jena, Germany)
epifluorescence equipment.

RESULTS
Characterization of the cleavage of mini-profibrillin-1
To characterize the carboxy-terminal cleavage site of
profibrillin-1, we designed a construct (p(LEEC)DNA3)
encoding a mini-profibrillin-1 protein with the unique amino
and carboxyl termini of profibrillin-1, and a central region of
the fibrillin-1 protein encoded by exons 23-44 (Fig. 1). The
central region of fibrillin was chosen because we have inferred
from the clustering of mutations in neonatal Marfan syndrome
in exons 24-32 that this region is critical for microfibril
formation (Kainulainen et al., 1994; Putnam et al., 1996). An
additional construct (p(LEE)DNA3) lacked the carboxyl
terminus and the protein produced by this construct was termed
short-fibrillin (Fig. 1). The in vitro transcription/translation of
p(LEEC)DNA3 and p(LEE)DNA3 produced proteins of 175
and 155 kDa, respectively (Fig. 3). Without reduction, both
proteins showed faster migration with blurred bands, indicating
that the proteins had spontaneously attained a disulfide-bridgemediated conformation (data not shown). Both proteins were
immunoprecipitated by a polyclonal antibody generated
against the protein domains encoded by exons 37-39 (data not
shown).
To test the hypothesis that members of the furin/PACE
family recognize the cleavage motif in the C terminus, miniprofibrillin was incubated with protein proconvertases
furin/PACE, PACE4, PC1/3 and PC2. Exposure to any of the
enzymes resulted in the proteolytic processing of miniprofibrillin to a fragment that was 15.8 kDa smaller (termed
mini-fibrillin) (Fig. 3). This processing was inhibited in the
presence of EGTA. Short-fibrillin was not cleaved, indicating
that the cleavage of mini-profibrillin occurred in the carboxyl
terminus. Incubation with an R-R/K-R-X endoprotease created
additional fragments for both proteins, indicating that the
proprotein convertases recognized only the basic amino acid
cleavage site in the carboxyl terminus (Fig. 3). Incubation of
radiolabelled mini-profibrillin with dermal fibroblasts also
resulted in the creation of mini-fibrillin (Fig. 4). Again, shortfibrillin was not detectably trimmed and the cleavage did not
occur in the presence of EGTA. Conditioned media from
dermal fibroblast cultures also contained converting activity,
albeit to a lesser extent (data not shown). Incubation of miniprofibrillin with LoVo cells also resulted in complete
conversion of mini-profibrillin to mini-fibrillin (Fig. 4).
Characterization of the cleavage site through sitedirected mutagenesis of the basic amino acids in
the P1, P2, P4 and P6 position
Earlier studies had shown that the furin/PACE family of
proteases are all dependent on an arginine in the P1 position.
Arginine 2731 in the P1 position of the carboxyl terminus
cleavage motif of mini-profibrillin was changed to serine using
site-directed mutagenesis to confirm the site of proteolytic
processing (Fig. 2). This substitution prevented the cleavage of
mini-profibrillin by both fibroblast cultures and proprotein
convertases (Fig. 4). Therefore, the site of processing in the
carboxy-terminal domain was more precisely mapped to the
basic amino acid cleavage consensus sequence.
To further characterize the cleavage site requirements for the
PACE/furin-like enzyme processing the mini-profibrillin
protein, site-directed mutagenesis was used to alter the basic
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Fig. 1. Structure of wild-type profibrillin-1 (from Pereira et al., 1993) and derived mini-constructs used in this study. The mini-profibrillin
construct [p(LEE)DNA3] contains the proper signals for initiation of translation and secretion from the cell. Mini-profibrillin consists of these
profibrillin domains: the amino terminus, a central portion encoded by exons 23-44, and the complete carboxyl terminus harboring the putative
proteolytic processing site (cleavage site). The short-fibrillin construct [p(LEE)DNA3] predicts a protein lacking the entire carboxyl terminus
including the putative cleavage site.

amino acids at the cleavage site. The amino acids in the P1,
P2, P4 and P6 positions were altered to neutral amino acids,
either serine or alanine (Fig. 2). The P6 arginine was also
altered to a tryptophan to recreate the spontaneous FBN1
mutation that prevented processing of wild-type profibrillin
(R2726W) (Milewicz et al., 1995). The recominant proteins
were then exposed to dermal fibroblasts for 24 hours, and the
percentage of the protein processed was determined (Fig. 5).
Similar to altering the arginine in the P1 position, altering the
basic amino acid in the P4 position completely prevented
cleavage. Interestingly, altering the P6 arginine to a tryptophan
completely prevented cleavage, but altering the P6 arginine to
an alanine only slowed the rate of cleavage. Altering the P2
arginine only slightly slowed cleavage. Therefore, the P1 and
P4 arginines are required for cleavage, whereas the
requirement of the P6 arginine is dependent on the amino acid
to which it is altered.
Profibrillin conversion as a prerequisite for
microfibrillogenesis and extracellular matrix
deposition
To assess the extent to which unconverted wild-type
profibrillin was incorporated into the extracellular matrix of
cultured fibroblasts, the irreversible furin peptide-inhibitor
DecRVKR-CMK was used to prevent profibrillin proteolytic
precessing (Garten et al., 1994). This compound inhibited

profibrillin conversion completely at a concentration of 50
µM in control fibroblasts (Fig. 6A). To assure complete
inhibition, 75 µM of inhibitor was added every 8 hours during
a 24-hour-chase metabolic labeling experiment. The inhibitor
did not affect the incorporation of labeled compounds into
cellular components (data not shown), general protein
synthesis or protein secretion (Fig. 6B), or cell viability as
monitored by Trypan Blue. In control cells without inhibitor
present, processed fibrillin was the predominant form in the
culture medium, and only processed fibrillin could be
Position (P)
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Fig. 2. Cleavage site (C) in the carboxyl terminus of profibrillin-1.
The P position nomenclature is assigned according to Schecter and
Berger (1967). The amino acids altered are underlined and in bold.
The asterisk indicates the mutation that recreates the spontaneous
FBN1 mutation (R2726W) that prevents profibrillin cleavage
(Milewicz et al., 1995).
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Fig. 3. In vitro cleavage of mini-profibrillin (miniproFib) and short-fibrillin (short-Fib) by four
proprotein convertases. Incubation of miniprofibrillin with any of the proteases results in the
cleavage of mini-profibrillin to a single fragment
(mini-fibrillin), approximately 20 kDa smaller
(lanes 3-6 from the left). No cleavage occurs in the
presence of either culture media from mocktransfected COS-1 cells or EGTA (lanes 1 and 2).
The short-fibrillin protein is not cleaved (lanes 912). In contrast, an Arg-Arg/Lys-Arg-X
endoprotease produces several fragments with
both proteins (lanes 7 and 13). In vitro
transcription/translation was performed with a
rabbit reticulocyte lysate system using 1 µg of
each plasmid DNA in the presence of
[35S]cysteine. Proteins were analyzed by SDSPAGE using a 7% polyacrylamide gel in the
presence of 10% mercaptoethanol. The removed
propeptide of miniprofibrillin is not visible
because it does not contain cysteine.

recovered from the extracellular matrix by a stringent
extraction procedure (Fig. 6B) (Hedman et al., 1979). In
cultures treated with DecRVKR-CMK, however, only
profibrillin was present in the culture medium, demonstrating
the efficient inhibition of profibrillin conversion. Analysis of
the extracellular matrix of treated cultures revealed the
absence of fibrillin and only trace amounts of unconverted
profibrillin (Fig. 6B). We also studied fibrillin deposition in
the fibroblast strain harboring the R2726W mutation in FBN1
that eliminates the P6 arginine in the cleavage site of wildtype profibrillin. Culture media obtained from these cells
contained profibrillin and fibrillin, whereas the extracellular
matrix of these cells predominantly contained fibrillin and
only trace amounts of profibrillin. Addition of the furin
inhibitor greatly diminished fibrillin deposition in the
extracellular matrix.

Morphological effects of impaired profibrillin
conversion in cell culture
The presence of the furin inhibitor caused a diminished
microfibrillar meshwork, which was only faintly
immunofluorescent under identical excitation conditions (Fig.
7a,b). Optimized excitation by laser scanning, however,
revealed that the density and wovenness of the fibrillincontaining microfibrillar network was comparable to that of the
control cells (Fig. 7c,d). Using standard immunofluorescence
techniques, individual microfibrils were thinner (Fig. 7g,h).
DISCUSSION
In this study we have demonstrated that profibrillin undergoes
carboxy-terminal cleavage by a furin/PACE-like protease. The

Fig. 4. Substitution of a serine for arginine in the P1
position abrogates conversion of mini-profibrillin.
PACE digests of radiolabelled recombinant proteins
were performed as in Fig. 3 (lanes 5-7). Lanes 2-4
show PACE digests in the presence of EGTA. The
mutagenized mini-profibrillin with a substitution of
the P1 arginine by serine (P1-mut) cannot be cleaved
by PACE. When these proteins were added to
hyperconfluent fibroblast cultures or the cell line
LoVo, mini-profibrillin (mini-proFib, lanes 9 and 11)
was cleaved to mini-fibrillin. The short-fibrillin (short
Fib, lane 8) and the P1-mutated mini-profibrillin were
not cleaved (lane 10). Note that short-fibrillin migrates
slightly faster than mini-fibrillin. This is due to a
predicted difference of 39 amino acids between the
two proteins. Lane 1 shows culture medium from
metabolically labelled fibroblasts; the asterisk
indicates wild-type profibrillin and fibrillin. The
positions of molecular mass markers (kDa) are shown.
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Fig. 5. Analysis of mini-profibrillin processing
by hyperconfluent dermal fibroblasts.
Following in vitro transcription/translation,
peptide products were exposed to
hyperconfluent dermal fibroblasts, or incubated
at 37°C without exposure to fibroblasts, for 24
hours. The samples were separated by SDSPAGE and visualized by autoradiography.
Lanes are labeled M (molecular mass
markers), –, without and +, with exposure to
fibroblasts. Molecular masses of 14C-labeled
markers are indicated on the left side, the
migration of mini-proFib and mini-Fib on the
right side. Specific mutants are indicated above
the figure.

lipophilic and intracellularly active furin-inhibitor decanoyl-RV-K-R-chloromethylketone inhibited profibrillin conversion in
cell culture (Garten et al., 1994). The inhibition could occur in
three ways: inhibition of secreted or cell membrane-associated
furin/PACE, cross-inhibition of the genuine profibrillin
convertase, or inhibition of the activation of the genuine
profibrillin convertase by furin/PACE (proprotein convertases
contain the R-X-K-R motif near the amino terminus and
cleavage at this site is required for activation). Further support
that a furin-like enzyme is responsible for the cleavage is the

fact that recombinantly expressed furin/PACE, PACE4, PC1/3
and PC2 were all able to cleave the mini-profibrillin protein,
although activation of another protease by these expressed
enzymes cannot be excluded. The scissile bond was identified
between the P1 arginine 2731 and the P1′ serine 2732 by sitedirected mutagenesis of the arginine, which inhibited
processing by both fibroblasts and furin/PACE. The basic
amino acid requirements at the cleavage site in profibrillin were
further characterized by altering the P2, P4 and P6 basic amino
acids, then testing the ability of human fibroblasts to cleave the

B

A

Fig. 6. (A) Variable amounts of the furin-inhibitor DecRVKR-CMK were applied to confluent fibroblast cultures as a single dose during a 4hour pulse period with [35S]cysteine, after preincubation for 1 hour. There is a clear dose-dependent inhibition of the conversion of profibrillin
(proFib) to fibrillin (Fib), which is completely inhibited at 50 µM. FN, fibronectin. (B) Only converted profibrillin is deposited into the
extracellular matrix. Cells from normal dermal fibroblasts and the fibroblast line heterozygous for the R2726W mutation (P6 mutation of the
profibrillin cleavage site) were pulsed for 1 hour with [35S]cysteine and chased for 24 hours. The furin inhibitor DecRVKR-CMK was added
after preincubation of the cells for 1 hour and fresh inhibitor was added every 8 hours. The presence of profibrillin (proFib) and fibrillin (Fib)
was monitored in culture medium (M) and extracellular matrix extracts (ECM). When conversion of profibrillin to fibrillin was blocked, no
fibrillin or profibrillin was deposited in the extracellular matrix. Note that the deposition of the extracellular matrix fibronectin (FN), which
does not contain a tetrabasic cleavage site for proprotein convertases of the furin/PACE family, is not affected.
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Fig. 7. Morphological appearance of the microfibrillar matrix in
cultured fibroblasts after inhibition of the profibrillin to fibrillin
conversion. Hyperconfluent normal fibroblasts were treated with 100
µM of the furin inhibitor DecRVKR-CMK (b,d,f,h) every 12 hours for
a further 48 hours, and the control culture with vehicle only (a,c,e,g).
The microfibrillar meshwork was visualized by indirect
immunofluorescence labeling of fibrillin (a-d). (a,b) An extended focus
view as obtained by confocal laser scanning under identical excitation
conditions. This analysis reveals markedly diminished microfibril
deposition in the treated culture (b) in comparison to the control (a).
Analysis of a 0.6 µm optical section at high magnification of the
control culture (c) and with increased laser output for optimized signal
yield in the treated culture (d) reveals that the density and wovenness
of the microfibrillar matrix is mainly comparable with a prevalence of
thinner microfibrils giving a sharp linear immunostaining signal (d).
(e,f) Phase-contrast images scanned from the identical areas as in a-d,
demonstrating comparable cell density and cell shape in the treated
cultures. (g,h) Conventional immunofluorescence with automatic
exposure time reveals the overall appearance of thinned microfibrils in
the treated cultures. Bars, 20 µm.

mutant mini-profibrillin protein. The P4 basic amino acid was
required for cleavage; altering this amino acid also completely
prevented cleavage. Altering the P6 arginine slowed cleavage
when it was mutated to an alanine, but completely prevented
cleavage when mutated to a tryptophan. These results help to
validate the experimental system, since the spontaneous
profibrillin mutation (R2726W), altering the P6 arginine to a
tryptophan, prevents processing of profibrillin (Milewicz et al.,
1995). The characterization of the cleavage site allowed the
exclusion of PC1/3 and PC2 as profibrillin convertases since
these enzymes required only dibasic amino acids at the
cleavage site (either R-R or K-R). In general, it is found that
furin/PACE prefers to cleave precursors at the general R/K-XR-X-R/K-R↓ motif (Rehemtulla et al., 1992; Seidah et al.,
1997), similar to the characterized motif for profibrillin. The
basic amino acids required for PACE4 cleavage are similar to
those for furin/PACE (Rehemtulla et al., 1993). PC5 has been
shown to best cleave precursors with R-X-X-R↓. The cleavage
motifs for the other convertases have not been well
characterized.
It should be noted that the amino terminus of profibrillin-1
also contained an R-X-K-R-R site, predicting the removal of
about 20 amino acids (Pereira et al., 1993). Recent
observations suggested that this cleavage site was used with the
eukaryotically expressed amino-terminal half of fibrillin-1 that
contained the addition of the BM40 leader sequence before the
regular fibrillin leader sequence (Reinhardt et al., 1996). We
have also studied the cleavage of the amino-terminal domain
of the mini-profibrillin construct by both CHO-K1 cells and
baculovirus cells (unpublished). Amino-terminal sequencing
of secreted protein revealed leader sequence processing at two
sites: between glycine 24 and alanine 25, and between alanine
27 and asparagine 28. Both eukaryotic systems also cleaved
the protein in the carboxy-terminal domain of the protein.
Further studies are needed to determine if the amino-terminal
site is cleaved in vitro, and the role this cleavage plays in the
incorporation of fibrillin into the matrix.
Based on the basic amino acids required for cleavage, only
PC1/3 and PC2 can be excluded as the enzymes responsible
for processing profibrillin. PC4 is expressed in germ cells, so
it is not a likely candidate for the convertase responsible for
profibrillin processing. Furin/PACE, the best-characterized
member of the subtilisin-like family, is ubiquitously expressed
and is a membrane-bound enzyme that is active in the transGolgi network, but is known to cycle between the trans-Golgi
and the cell surface (Klimpel et al., 1992). Recombinant
overexpressed PACE can be secreted into the medium,
suggesting that a similar pathway may exist for cells that
naturally express PACE (Vey, 1994; Creemers et al., 1996).
PC5 and PC7 are widely expressed and are located in dense
core secretory granules and the trans-Golgi network. PC5 does
not have a transmembrane domain, whereas PC7 does. PACE4
is also widely expressed but little is known about its cellular
localization. Of interest is the fact that LoVo cells synthesize
primarily PACE4 and an inactive furin/PACE, but are shown
here to be able to cleave the mini-profibrillin protein
(Takahashi et al., 1995; Seidah et al., 1994). Therefore, many
of the furin-like enzymes, including PC5, PC7 and PACE4, are
candidates for the enzyme responsible for profibrillin
processing. The ability of many of the expressed furin/PACElike enzymes to properly process the mini-profibrillin indicates
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that the enzyme responsible for the proteolytic processing may
be dependent on which of the enzymes are expressed by the
cells that are synthesizing profibrillin.
The exclusion of profibrillin from the matrix in the presence
of the furin inhibitor provides evidence that profibrillin
processing is necessary for matrix incorporation. The
observation that fewer microfibrils are formed when
profibrillin processing is prevented by the furin inhibitor also
helps to establish that profibrillin processing is necessary for
the incorporation of fibrillin into microfibrils, although the
furin inhibitor could potentially be acting on other proteins
necessary for microfibril formation. The clinical relevance of
the proprotein convertases is significant, since these enzymes
are involved in the processing of neuropeptides, neurotrophins,
growth factors, renin, endothelin, HIV, insulin and related
peptides, and parathormone and parathormone-like peptides,
and matrix metalloproteases (Seidah et al., 1994; Pei and
Weiss, 1995). The evidence presented here adds profibrillin to
the list of proteins that are processed by the PACE/furin family
of enzymes, the first extracellular matrix protein that has been
shown to be processed by these enzymes. Impaired profibrillin
processing, such as that due to the R2726W mutation identified
in an individual with isolated skeletal features of Marfan
syndrome, suggests that the availability of fibrillin for
microfibrillogenesis during skeletal development is crucial
(Milewicz et al., 1995). This fact raises the possibility that the
profibrillin convertase is a modulator of skeletal growth.
Accordingly, mutations can be envisaged that impair
profibrillin convertase and result in skeletal features of Marfan
syndrome.
The furin inhibitor was a generous gift from Dr Herbert Angliker,
Friedrich Miescher Institute in Basel, Switzerland. mAb69 against
fibrillin was kindly given by Dr Robert Glanville, Portland, Oregon
and the polyclonal antibody against fibrillin-1 modules 37-39 by Dr
Maureen Boxer, London. This work was supported by the Deutsche
Forschungsgemeinschaft grants Ra 447/3-1 and 3-2 (M.R.) and a NIH
RO1 AR43626A (D.M.M.).
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